GEN Exclusives

More »

Feature Articles

More »
Oct 1, 2012 (Vol. 32, No. 17)

Animal Models Get Closer to Mimicking Humans

  • Animal models contribute significantly to our understanding of molecular mechanisms underlying disease pathologies. However, few models predictably translate preclinical findings into what will happen in humans.

    Investigational drugs are able to cure mice from many diseases, but continue to fail in clinical trials. This fact is largely attributed to poor model designs that do not sufficiently reflect the pathophysiology of disease in humans. In addition, tremendous diversity of human genetic background, co-medications, dosing, timing of treatment, and many other factors greatly influence the treatment outcome.

    The new generation of animal models, described in this article, takes into consideration previous shortcomings. These models aim to reflect the human condition as closely as possible and to close the gap between translational research and the bedside.

    Inbred lab mouse strains with fixed and highly reproducible genotypes are a powerful tool for genetic manipulation. Mouse embryonic stem cells are easily amenable to genetic modifications, and thousands of genetically modified mouse strains were developed in the last 20 years.

    “And yet, the inbred lab strains proved to be a poor system for discovery of specific genes associated with a particular trait, such as obesity or high blood pressure,” comments Gary A. Churchill, Ph.D., professor and principal investigator, The Jackson Laboratory.

    “This is a result of their limited genetic diversity and large ‘blind spots’ largely devoid of genetic variations. We cannot resolve trait association at the level of an individual gene.

    “In contrast, human genome association studies map individual genes to traits with a high degree of accuracy, but this is not enough to make a conclusive disease diagnosis.

    “Therefore, discovery of a genetic basis of a complex trait required a radically new genetic strategy.”

    Jackson Labs is a key participant in the International Collaborative Cross (CC) project, with the goal to create new types of inbred strains based on eight parents selected from the existing laboratory and wild strains.

    “CC mice demonstrate high levels of genetic diversity,” continues Dr. Churchill. “Jackson Labs used this opportunity to take CC ideas to the next level.”

    The same progenitor lines served as the parent lines for the JAX Diversity Outbred (DO) Population. This unique mouse population is maintained by a carefully designed outbreeding strategy. While still not as diverse as humans, DO mice more accurately reflect human genetic architecture and may provide better insight into genetic mechanisms of human diseases.

    “The DO animals proved to be an excellent tool for mapping trait-associated loci to a higher level of resolution,” says Dr. Churchill.

    Using DO mice, his team mapped a cluster of genes conferring sensitivity to doxyrubicine, a common chemotherapy agent. Within the cluster, protective, susceptible and neutral alleles were identified. The Jackson lab is collaborating with the National Institute for Environmental Health and Safety to identify susceptibility genes for other environmental pollutants.

    “We hope that in the future these results will support toxicology analysis of human therapeutics,” says Dr. Churchill.

  • Linking Genotype with Phenotype

    Genetics of the outbred mouse population seem to provide theoretical consistency with human population,” agrees Michael D. Hayward, Ph.D., group leader, Taconic.

    “However, it would be difficult to use such a population as a model to study function of individual genes. Taconic fully recognizes the profound influence of the genetic background of inbred strains on the phenotype. But we use this fact to our advantage to design our phenotyping methodology.”

    The genetic background of lab mice may vary even between populations of the same strain maintained at different locations. Such sub-populations accumulate minor polymorphisms, leading to “genetic drifts.” To control for the background diversity in their phenotyping experiments, Taconic produces a litter of heterozygous progeny of a genetically engineered mouse (knockout or transgenic) that are congenic to a characterized background strain.

    The second cross of heterozygous littermates produces mice that are genetically identical except for the gene of interest. This approach is especially important to correlate for subtle phenotypical manifestations such as behavioral or psychiatric changes.

    To tease out these differences, Taconic developed what essentially represents a high-throughput screening of animal phenotypes in vivo. Marketed as “PhenoTac,” the analysis platform is a panel of fully validated assays representing several therapeutic areas of interest (i.e., obesity, diabetes, inflammation, neurology).

    “In contrast with traditional approaches that use a large number of mice to achieve statistical significance, we conduct PhenoTac assays in the same animals, which decreases the number of mice and associated breeding costs,” continues Dr. Hayward.

    “To perform phenotypic assessment of each genetic modification on most of the major aspects of mouse physiology we need only 40 experimental animals and the same number of controls. This is 10 times less than what would be required otherwise.

    “Validation of our sequential strategy confirmed that the outcomes of the assays conducted later in the sequence are not affected by assays conducted in the beginning.”

    Using its breeding approach and PhenoTac analysis, Taconic uncovered numerous clinically relevant phenotypes in laboratory strains with targeted and spontaneously occurring mutations.

    “Our next step is to harness the power of the platform to study novel therapeutic compounds,” says Dr. Hayward. “In collaboration with industry partners, we plan to characterize phenotypes of animals carrying selected human genes. Using this carefully designed strategy, genetically modified mice can provide information for drug development that is not practical using any other method.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?